The role of Thymosin β4 in angiotensin II-induced cardiomyocytes growth

References

• Berenji K, Drazner MH, Rothermel BA, et al. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol. 2005;289(1):H8–H16.
   PubMed Web of Science ®Google Scholar
• Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006;7(8):589–600.
   PubMed Web of Science ®Google Scholar
• Carreno JE, Apablaza F, Ocaranza MP, et al. Cardiac hypertrophy: molecular and cellular events. Rev Esp Cardiol. 2006;59(5):473–486.
   PubMed Web of Science ®Google Scholar
• Frey N, Katus HA, Olson EN, et al. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109(13):1580–1589.
   PubMed Web of Science ®Google Scholar
• Chien KR, Zhu H, Knowlton KU, et al. Transcriptional regulation during cardiac growth and development. Annu Rev Physiol. 1993;55:77–95.
   PubMed Web of Science ®Google Scholar
• Kavey RE. Left ventricular hypertrophy in hypertensive children and adolescents: predictors and prevalence. Curr Hypertens Rep. 2013;15(5):453–457.
   PubMed Web of Science ®Google Scholar
• Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A. 1981;78(2):1162–1166.
   PubMed Web of Science ®Google Scholar
• Bonnet D, Lemoine FM, Pontvert-Delucq S, et al. Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors. Blood. 1993;82(11):3307–3314.
   PubMed Web of Science ®Google Scholar
• Goldstein AL, Hannappel E, Sosne G, et al. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37–51.
   PubMed Web of Science ®Google Scholar
• Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474–481.
   PubMed Web of Science ®Google Scholar
• Mollinari C, Ricci-Vitiani L, Pieri M, et al. Downregulation of thymosin beta4 in neural progenitor grafts promotes spinal cord regeneration. J Cell Sci. 2009;122(Pt 22):4195–4207.
   PubMed Web of Science ®Google Scholar
• Sosne G, Qiu P, Goldstein AL, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144–2151.
   PubMed Web of Science ®Google Scholar
• Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466–472.
   PubMed Web of Science ®Google Scholar
• Sopko N, Qin Y, Finan A, et al. Significance of thymosin beta4 and implication of PINCH-1-ILK-alpha-parvin (PIP) complex in human dilated cardiomyopathy. PLoS One. 2011;6(5):e20184.
   PubMed Web of Science ®Google Scholar
• Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177–182.
   PubMed Web of Science ®Google Scholar
• Wei C, Kim IK, Li L, et al. Thymosin Beta 4 protects mice from monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. PLoS One. 2014;9(11):e110598.
   PubMed Web of Science ®Google Scholar
• Kumar S, Gupta S. Thymosin beta 4 prevents oxidative stress by targeting antioxidant and anti-apoptotic genes in cardiac fibroblasts. PLoS One. 2011;6(10):e26912.
   PubMed Web of Science ®Google Scholar
• Hinkel R, El-Aouni C, Olson T, et al. Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection. Circulation. 2008;117(17):2232–2240.
   PubMed Web of Science ®Google Scholar
• Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res. 2011;89(2):265–272.
   PubMed Web of Science ®Google Scholar
• Espira L, Czubryt MP. Emerging concepts in cardiac matrix biology. Can J Physiol Pharmacol. 2009;87(12):996–1008.
   PubMed Web of Science ®Google Scholar
• Zuo Y, Chun B, Potthoff SA, et al. Thymosin beta4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis. Kidney Int. 2013;84(6):1166–1175.
   PubMed Web of Science ®Google Scholar
• Reyes-Gordillo K, Shah R, Popratiloff A, et al. Thymosin-beta4 (Tbeta4) blunts PDGF-dependent phosphorylation and binding of AKT to actin in hepatic stellate cells. Am J Pathol. 2011;178(5):2100–2108.
   PubMed Web of Science ®Google Scholar
• Omata M, Taniguchi H, Koya D, et al. N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis. J Am Soc Nephrol. 2006;17(3):674–685.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International forum on cardiac remodeling. J Am Coll Cardiol. 2000;35(3):569–582.
   PubMed Web of Science ®Google Scholar
• Harvey PA, Leinwand LA. The cell biology of disease: cellular mechanisms of cardiomyopathy. J Cell Biol. 2011;194(3):355–365.
   PubMed Web of Science ®Google Scholar
• Komuro I, Yazaki Y. Control of cardiac gene expression by mechanical stress. Annu Rev Physiol. 1993;55:55–75.
   PubMed Web of Science ®Google Scholar
• McKinsey TA, Kass DA. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov. 2007;6(8):617–635.
   PubMed Web of Science ®Google Scholar
• Shioi T, McMullen JR, Kang PM, et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol. 2002;22(8):2799–2809.
   PubMed Web of Science ®Google Scholar
• Hinkel R, Trenkwalder T, Petersen B, et al. MRTF-A controls vessel growth and maturation by increasing the expression of CCN1 and CCN2. Nat Commun. 2014;5:3970.
   PubMed Web of Science ®Google Scholar
• Li L, Guleria RS, Thakur S, et al. Thymosin beta4 prevents angiotensin II-induced cardiomyocyte growth by regulating Wnt/WISP signaling. J Cell Physiol. 2016;231(8):1737–1744.
   PubMed Web of Science ®Google Scholar
• Tzahor E, Lassar AB. Wnt signals from the neural tube block ectopic cardiogenesis. Genes Dev. 2001;15(3):255–260.
   PubMed Web of Science ®Google Scholar
• Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006;281(32):22429–22433.
   PubMed Web of Science ®Google Scholar
• Daskalopoulos EP, Hermans KC, Janssen BJ, et al. Targeting the Wnt/frizzled signaling pathway after myocardial infarction: a new tool in the therapeutic toolbox? Trends Cardiovasc Med. 2013;23(4):121–127.
   PubMed Web of Science ®Google Scholar
• Cingolani OH. Cardiac hypertrophy and the Wnt/Frizzled pathway. Hypertension. 2007;49(3):427–428.
   PubMed Web of Science ®Google Scholar
• Bergmann MW. WNT signaling in adult cardiac hypertrophy and remodeling: lessons learned from cardiac development. Circ Res. 2010;107(10):1198–1208.
   PubMed Web of Science ®Google Scholar
• Haq S, Michael A, Andreucci M, et al. Stabilization of beta-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth. Proc Natl Acad Sci U S A. 2003;100(8):4610–4615.
   PubMed Web of Science ®Google Scholar
• Qu J, Zhou J, Yi XP, et al. Cardiac-specific haploinsufficiency of beta-catenin attenuates cardiac hypertrophy but enhances fetal gene expression in response to aortic constriction. J Mol Cell Cardiol. 2007;43(3):319–326.
   PubMed Web of Science ®Google Scholar
• Malekar P, Hagenmueller M, Anyanwu A, et al. Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling. Hypertension. 2010;55(4):939–945.
   PubMed Web of Science ®Google Scholar
• Laeremans H, Hackeng TM, van Zandvoort MA, et al. Blocking of frizzled signaling with a homologous peptide fragment of wnt3a/wnt5a reduces infarct expansion and prevents the development of heart failure after myocardial infarction. Circulation. 2011;124(15):1626–1635.
   PubMed Web of Science ®Google Scholar
• Saraswati S, Alfaro MP, Thorne CA, et al. Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair and post-MI cardiac remodeling. PLoS One. 2010;5(11):e15521.
   PubMed Web of Science ®Google Scholar
• ter Horst P, Smits JF, Blankesteijn WM. The Wnt/Frizzled pathway as a therapeutic target for cardiac hypertrophy: where do we stand? Acta Physiol (Oxf). 2012;204(1):110–117.
   PubMed Web of Science ®Google Scholar
• Xu L, Rb C, Jw W, et al. WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev. 2000;14(5):585–595.
   PubMed Web of Science ®Google Scholar
• Zelarayan LC, Noack C, Sekkali B, et al. Beta-Catenin downregulation attenuates ischemic cardiac remodeling through enhanced resident precursor cell differentiation. Proc Natl Acad Sci U S A. 2008;105(50):19762–19767.
   PubMed Web of Science ®Google Scholar
• Zelarayan LC, Noack C, Zafiriou MP, et al. Wnt signaling molecules in left ventricular remodeling: focus on dishevelled 1. Hypertension. 2010;55(4):852–854.
   PubMed Web of Science ®Google Scholar
• Colston JT, de la Rosa SD, Koehler M, et al. Wnt-induced secreted protein-1 is a prohypertrophic and profibrotic growth factor. Am J Physiol Heart Circ Physiol. 2007;293(3):H1839–1846.
   PubMed Web of Science ®Google Scholar
• Baurand A, Zelarayan L, Betney R, et al. Beta-catenin downregulation is required for adaptive cardiac remodeling. Circ Res. 2007;100(9):1353–1362.
   PubMed Web of Science ®Google Scholar